Revenue
disaggregated by product for the three and nine months ended September 30, 2026 and 2025 is as follows:
SCHEDULE
OF DISAGGREGATED BY PRODUCT
| Product | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Nine Months Ended | |
| | |
September 30, | | |
September 30, | |
| Product | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| ARBLI™ (SCN-102, Losartan Potassium Oral Suspension) | |
$ | 329,783 | | |
$ | - | | |
$ | 729,747 | | |
$ | - | |
| REZENOPY™ (naloxone HCl nasal spray, 10 mg) | |
| 924,794 | | |
| - | | |
| 924,794 | | |
| - | |
| Pharmaceutical product resale | |
| - | | |
| 590,050 | | |
| - | | |
| 600,308 | |
| Total revenues | |
$ | 1,254,577 | | |
$ | 590,050 | | |
$ | 1,654,541 | | |
$ | 600,308 | |
|